As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical differentiator for pharma companies.
The transformative potential of artificial intelligence (AI) within medical affairs has been widely discussed, yet, realising its real-world commercial value requires a pragmatic approach t
With the hype around generative AI (GenAI), there is an increasing demand to explore its capabilities across pharma and MedTech companies, as well as contract research organisations.